**Supplementary Table 1**

|  |
| --- |
| BASELINE PATIENT CHARACTERISTICS |
| Treated (# of pts) | **25** |
| Median Age, years (range) | **66 (46-84)** |
| Race White Other | **20 (80%)****5 (20%)** |
| ECOG, # of pts 0 1 | **12 (48%)****13 (52%)** |
| PSA (ng/ml) Median (range) | **26.9 (<0.1-4,170)** |
| Total Alkaline Phosphatase, Nl 38-126 U/L Median (range) | **124 (64-681)** |
| LDH, Nl 313-618 U/L Median (range) | **489 (370-1098)** |
| Hemoglobin, Nl 14-18 gm/dL Median (range) | **12.0 (8.8-15.1)** |
| Albumin, Nl 3.5-4.7 gm/dL Median (range) | **4.3 (3.7- 4.9)** |
| Prior Taxane, # of pts | **18 (72%)** |
| Prior Abiraterone and/or Enzalutamide  # of pts | **20 (80%)** |
| Gleason Score, # of pts 7 8 9 10Unknown | **3****5****14****1****2** |
| Extent of Bone Metastases, # of pts <20 >20 | **8 (32%)****17 (68%)** |
| Median Follow Up, months  | **27.6**  |

**Supplementary Table 2**

|  |  |  |
| --- | --- | --- |
| **# of Cycles** | **Favorable OS****(# of patients)** | **Unfavorable OS****(# of patients)** |
| 6 | 12 | 7 |
| 5 | 1 | 1 |
| 4 | - | - |
| 3 | - | 2 |
| 2 | - | 1 |
| 1 | - | 1 |

**Supplementary Table 3**

|  |  |  |
| --- | --- | --- |
| **OS (months)** | **Censor 1=Died 0=Alive** |  |
| 3.3 | 1 | **Unfavorable** |
| 5.3 | 1 |
| 6.3 | 1 |
| 7.9 | 1 |
| 8.5 | 1 |
| 12.6 | 1 |
| 15.3 | 1 |
| 16.0 | 1 |
| 18.1 | 1 |
| 18.2 | 1 |
| 18.9 | 1 |
| 19.4 | 1 |
| 23.1 | 1 | **Favorable** |
| 24.3 | 1 |
| 24.9 | 1 |
| 27.2 | 0 |
| 31.4 | 1 |
| 35.5 | 1 |
| 36.3 | 0 |
| 36.8 | 0 |
| 36.9 | 0 |
| 38.7 | 0 |
| 39.5 | 0 |
| 42.8 | 0 |
| 43.1 | 0 |